Omalizumab for previously treated chronic spontaneous urticaria

  • Technology appraisal guidance
  • TA339
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by the Southampton Health Technology Assessments Centre (SHTAC):

  • Jones J, Cooper K, Picot J et al. Omalizumab for previously treated chronic spontaneous urticaria, September 2014

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document. Companies were also invited to make written submissions. Professional or specialist and patient or carer groups, and other consultees, had the opportunity to give their expert views. Companies, professional or specialist and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Company:

  • Novartis

Professional or specialist and patient or carer groups:

  • Allergy UK

  • British Association of Dermatologists

  • British Society for Allergy and Clinical Immunology

  • Royal College of Paediatrics and Child Health

  • Royal College of Pathologists

  • Royal College of Physicians

Other consultees:

  • Department of Health

  • NHS England

  • Welsh Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on omalizumab by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the appraisal consultation document.

  • Dr Clive Grattan, Consultant Dermatologist, Norfolk and Norwich University Hospital and St John's Institute of Dermatology, nominated by the British Association of Dermatologists – clinical expert

  • Dr Shuiab Nasser, Consultant in Allergy and Asthma, Cambridge University Hospitals NHS Foundation Trust, nominated by British Society for Allergy and Clinical Immunology – clinical expert

  • Dr Sinisa Savic, Consultant Clinical Immunologist, Leeds Teaching Hospitals NHS Trust, nominated by Novartis and by the Royal College of Pathologists– clinical expert

  • Mrs Maureen Jenkins, Clinical Director, Allergy UK, nominated by Allergy UK – patient expert

  • Mrs Deborah Shipman, nominated by Allergy UK– patient expert

Representatives from the following company or sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Novartis

ISBN: 978‑1‑4731‑1134‑9